Li Z - Search Results

1

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.

Hu L, Ren Q, Deng L, Zhou Z, Cai Z, Wang B, Li Z. Hu L, et al. Among authors: li z. Eur J Med Chem. 2021 Feb 5;211:113106. doi: 10.1016/j.ejmech.2020.113106. Epub 2020 Dec 16. Eur J Med Chem. 2021. PMID: 33360559

2

Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.

Li Z, Xu X, Deng L, Liao R, Liang R, Zhang B, Zhang L. Li Z, et al. Bioorg Med Chem. 2018 Aug 7;26(14):3947-3952. doi: 10.1016/j.bmc.2018.06.017. Epub 2018 Jun 14. Bioorg Med Chem. 2018. PMID: 29954682

3

Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.

Li Z, Zhou Z, Deng F, Li Y, Zhang D, Zhang L. Li Z, et al. Among authors: li y. Eur J Med Chem. 2018 Nov 5;159:267-276. doi: 10.1016/j.ejmech.2018.09.071. Epub 2018 Oct 1. Eur J Med Chem. 2018. PMID: 30296685

4

Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.

Li Z, Chen Y, Zhou Z, Deng L, Xu Y, Hu L, Liu B, Zhang L. Li Z, et al. Eur J Med Chem. 2019 Feb 15;164:352-365. doi: 10.1016/j.ejmech.2018.12.069. Epub 2018 Dec 27. Eur J Med Chem. 2019. PMID: 30605833

5

Design, synthesis and biological activity of deuterium-based FFA1 agonists with improved pharmacokinetic profiles.

Liu B, Deng L, Chen H, Liao R, Li Y, Zeng X, Deng F, Zhang L, Li Z. Liu B, et al. Among authors: li y, li z. Bioorg Med Chem Lett. 2019 Jun 15;29(12):1471-1475. doi: 10.1016/j.bmcl.2019.04.019. Epub 2019 Apr 10. Bioorg Med Chem Lett. 2019. PMID: 30992164

6

Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold.

Li Z, Ren Q, Wang X, Zhou Z, Hu L, Deng L, Guan L, Qiu Q. Li Z, et al. Bioorg Chem. 2019 Nov;92:103209. doi: 10.1016/j.bioorg.2019.103209. Epub 2019 Aug 16. Bioorg Chem. 2019. PMID: 31487621

7

Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.

Li Z, Hu L, Wang X, Zhou Z, Deng L, Xu Y, Zhang L. Li Z, et al. Bioorg Chem. 2019 Nov;92:103254. doi: 10.1016/j.bioorg.2019.103254. Epub 2019 Sep 6. Bioorg Chem. 2019. PMID: 31518760

8

Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease.

Li Z, Xu Y, Cai Z, Wang X, Ren Q, Zhou Z, Xie R. Li Z, et al. Bioorg Chem. 2020 Jun;99:103803. doi: 10.1016/j.bioorg.2020.103803. Epub 2020 Mar 31. Bioorg Chem. 2020. PMID: 32251945

9

Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM.

Ren Q, Deng L, Zhou Z, Wang X, Hu L, Xie R, Li Z. Ren Q, et al. Among authors: li z. Bioorg Chem. 2020 Aug;101:103963. doi: 10.1016/j.bioorg.2020.103963. Epub 2020 May 25. Bioorg Chem. 2020. PMID: 32480174

10

ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis.

Li Z, Zhou Z, Hu L, Deng L, Ren Q, Zhang L. Li Z, et al. Pharmacol Res. 2020 Sep;159:105035. doi: 10.1016/j.phrs.2020.105035. Epub 2020 Jun 17. Pharmacol Res. 2020. PMID: 32562818

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114,187 results

Search Page

Filters